The second license agreement with Solasia, announced today, brings funding support of expanding PledOx development into new combinations and indications, as well as an increase of the milestone package and further validation of the project. We believe the deal increases the likelihood that we will see new clinical studies starting next year with PledOx, as a pre-treatment to taxanes. This has not yet been included in our Pledpharma model, but still, we see considerable upside potential for the stock.